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Background: Previous analysis of COMBI-d (NCT01584648) demonstrated improved progression-free survival (PFS) and overall
survival (OS) with combination dabrafenib and trametinib versus dabrafenib monotherapy in BRAF V600E/K-mutant metastatic
melanoma. This study was continued to assess 3-year landmark efficacy and safety after36-month follow-up for all living
patients.
Patients and methods: This double-blind, phase 3 study enrolled previously untreated patients with BRAF V600E/K-mutant
unresectable stage IIIC or stage IV melanoma. Patients were randomized to receive dabrafenib (150mg twice daily) plus trameti-
nib (2mg once daily) or dabrafenib plus placebo. The primary endpoint was PFS; secondary endpoints were OS, overall
response, duration of response, safety, and pharmacokinetics.
Results: Between 4 May and 30 November 2012, a total of 423 of 947 screened patients were randomly assigned to receive
dabrafenib plus trametinib (n¼ 211) or dabrafenib monotherapy (n¼ 212). At data cut-off (15 February 2016), outcomes
remained superior with the combination: 3-year PFS was 22% with dabrafenib plus trametinib versus 12% with monotherapy,
and 3-year OS was 44% versus 32%, respectively. Twenty-five patients receiving monotherapy crossed over to combination ther-
apy, with continued follow-up under the monotherapy arm (per intent-to-treat principle). Of combination-arm patients alive at
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3 years, 58% remained on dabrafenib plus trametinib. Three-year OS with the combination reached 62% in the most favourable
subgroup (normal lactate dehydrogenase and<3 organ sites with metastasis) versus only 25% in the unfavourable subgroup
(elevated lactate dehydrogenase). The dabrafenib plus trametinib safety profile was consistent with previous clinical trial obser-
vations, and no new safety signals were detected with long-term use.
Conclusions: These data demonstrate that durable (3 years) survival is achievable with dabrafenib plus trametinib in patients
with BRAF V600-mutant metastatic melanoma and support long-term first-line use of the combination in this setting.
Key words: melanoma, metastatic, BRAF, dabrafenib, trametinib, durable outcomes
Introduction
Before recent therapeutic advances, the prognosis for patients
with metastatic melanoma was poor, with a 5-year survival of
6% and a median overall survival (OS) of 7.5months [1]. The
anti-cytotoxic T-lymphocyte-associated protein 4 (anti-CTLA-4)
therapy ipilimumab was the first agent to show durable clinical
benefit lasting5 years in a subset of patients within molecularly
unselected advanced melanoma populations [2]. More recently,
BRAF and MEK inhibitor (BRAFi/MEKi) combinations and
anti-programmed death-1 (anti-PD-1) checkpoint-inhibitor
immunotherapy regimens demonstrated significant improve-
ments in clinical outcomes in phase 3 trials of patients with meta-
static melanoma; however, extended follow-up in these studies
has been limited to2 years [3–9]. Targeted therapies have been
purported to be associated with rapid deterioration and death
following development of secondary resistance; however, evi-
dence from long-term, large randomized studies is lacking. With
multiple treatments now available for BRAF V600-mutant mela-
noma, a better understanding of the proportion and characteris-
tics of patients who can derive durable benefit and maintain
tolerability with long-term use of current therapies is needed for
optimizing treatment.
Combination dabrafenib and trametinib (DþT) demonstrated
improved progression-free survival (PFS) and OS over BRAFi
monotherapy in randomized phase 2 and 3 trials in patients with
BRAF V600E/K-mutant stage IIIC unresectable or stage IV meta-
static melanoma [3, 4, 10–13]. The DþT safety profile has been
consistent across these studies, in which the combination has been
associated with a reduction in hyperproliferative skin lesions [e.g.
squamous cell carcinoma (SCC), keratoacanthoma (KA)] com-
pared with BRAFi monotherapy, while the frequency and severity
of pyrexia appear higher [3, 4, 10].
In the most recent analysis of COMBI-d, a randomized, double-
blind, phase 3 trial of DþT versus dabrafenib monotherapy (dab-
rafenib plus placebo), with a median follow-up of 20.0months for
the DþT arm and 16.0months for the monotherapy arm,median
PFSwas 11.0 versus 8.8months [HR, 0.67; 95% confidence interval
(CI), 0.53–0.84; P¼ 0.0004], median OS was 25.1 versus
18.7months (HR, 0.71; 95% CI, 0.55–0.92; P¼ 0.0107), and 2-
year OS was 51% versus 42% [3]. These findings confirmed results
from the primary analysis of COMBI-d [12] and were consistent
with outcomes observed in the randomized phase 3 COMBI-v
study of DþT versus vemurafenib [4]. The longest follow-up to
date for DþT in a randomized study (median 45.6months) was
reported for the phase 2 BRF113220 study (part C) evaluating
DþT (n¼ 54) versus dabrafenib monotherapy (n¼ 54) [11], in
which DþT-treated patients had a 2- and 3-year PFS of 25% and
21%, respectively, and a 2- and 3-year OS of 51% and 38%, respec-
tively. Pooled data across these trials (median follow-up of
20.0months) showed that normal baseline serum lactate dehydro-
genase (LDH) and<3 organ sites containing metastasis were the
factors most predictive of durable outcomes; patients with both of
these characteristics had a 2-year PFS of 46% and a 2-year OS of
75% [14].
Here, we report an updated 3-year landmark analysis for the
phase 3 COMBI-d trial, including updated PFS, OS, best response
and safety analyses.
Methods
The COMBI-d study (protocol previously published [3] and further
described in the supplementary data, available at Annals of Oncology
online) was continued after prior primary and OS analyses [3, 12] to pro-
vide an updated 3-year landmark analysis of long-term outcomes.
Crossover was permitted following the previous OS analysis by patient/
physician discretion on the intent-to-treat principle, by which any cross-
over benefit was applied to the randomized therapy arm estimates.
Kaplan–Meier estimations of 2- and 3-year PFS and OS were carried out
to describe long-term outcomes. Influences of prognostic factors on
patient-derived benefit were explored with descriptive subgroup stratifi-
cation by baseline factors previously identified as being predictive of out-
comes in patients receiving DþT [14].
Results
Baseline characteristics were well balanced across 423 patients
randomly assigned to receive DþT (n¼ 211) or dabrafenib
monotherapy (n¼ 212; supplementary Figure S1 and Table S1,
available at Annals of Oncology online). At data cut-off, 15
February 2016, patients who were alive had36months of
follow-up from time of randomization. Forty (19%) DþT-arm
patients versus 6 (3%) monotherapy-arm patients remained on
randomized treatment.
At data cut-off, 3-year PFS was 22% for the DþT arm and
12% for the monotherapy arm [HR, 0.71 (95% CI, 0.57–0.88)]
(Figure 1A), and 3-year OS was 44% and 32%, respectively [HR,
0.75 (95% CI, 0.58–0.96)] (Figure 2A). Notably, 25 (12%)
patients in the dabrafenib monotherapy arm crossed over to
DþT, of which 6 (24%) had progressed on monotherapy before
crossover. Survival outcomes in these crossover patients, all of
whom remained on DþT as of data cut-off, continued to be fol-
lowed up under the monotherapy arm. Of combination-arm
patients who were progression free (n¼ 31) and alive (n¼ 76) at
3 years, 28 (90%) and 44 (58%) remained on DþT, respectively.
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As expected per the progression rate in each arm, more
monotherapy-arm patients received post-progression systemic
therapy versus DþT-arm patients [130/211 (62%) versus 101/
209 (48%); supplementary Table S2, available at Annals of
Oncology online]. In both the DþT and monotherapy groups,
immunotherapy was the most common subsequent anticancer
therapy (56% versus 56%, respectively); ipilimumab was the
most common immunotherapy (41% versus 50%), with fewer
patients receiving nivolumab (7% versus 5%) or pembrolizumab
(13% versus 11%).
Long-term PFS and OS consistently favoured DþT over
monotherapy, regardless of baseline prognostic factors. Three-
year PFS rates in patients with normal baseline LDH levels
[upper limit of normal (ULN), n¼ 273/423 (65%)] were 27%
in the DþT arm versus 17% in the monotherapy arm [HR, 0.70
(95% CI, 0.53–0.93)] (Figure 1B), and 3-year OS rates were 54%
versus 41%, respectively [HR, 0.74 (95% CI, 0.53–1.03)] (Figure
2B). Of 133 DþT-arm patients with LDHULN, 61 (46%)
were alive at 3 years and 34 (26%) remained on DþT. The great-
est clinical benefit with DþT was observed in patients with
LDHULN and<3 organ sites with metastasis at baseline
[n¼ 172/423 (41%)], with 3-year PFS rates of 38% in the combi-
nation arm versus 16% in the monotherapy arm [HR, 0.53 (95%
CI, 0.38–0.76)] (Figure 1C), and 3-year OS rates of 62% versus
45%, respectively [HR, 0.63 (95% CI, 0.41–0.99)] (Figure 2C). Of
76 combination-arm patients with baseline LDHULN and<3
organ sites with metastasis, 37 (49%) were alive at 3 years and 23
(30%) remained on DþT. In patients with baseline LDH>ULN
Subgroup n
PFS (95% CI) HR
(95% CI)2 year 3 year
Dabrafenib plus trametinib 211 30% (24–37) 22% (16–28)b 0.71 
(0.57–0.88)Dabrafenib plus placeboa 212 16% (12–22) 12% (7–18)
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Subgroup n
PFS (95% CI) HR 
(95% CI)2 year 3 year
Dabrafenib plus trametinib 133 37% (29–46) 27% (19–35) 0.70
(0.53–0.93)Dabrafenib plus placebo 140 21% (14–28) 17% (10–26)
Figure 1. Progression-free survival (PFS) in the dabrafenib and trametinib (Dþ T) and dabrafenib monotherapy [Dþ placebo (Pbo)] arms in
(A) the intent-to-treat population and patients with (B) normal baseline lactate dehydrogenase (upper limit of normal), (C) normal baseline
lactate dehydrogenase and<3 organ sites with metastasis, and (D) elevated baseline lactate dehydrogenase (>upper limit of normal). CI,
confidence interval; HR, hazard ratio.
aIncludes 25 patients who crossed over from monotherapy to the combination.
bOf Dþ T patients who were progression free at 3 years, 28 (90%) remained on Dþ T.
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[n¼ 147/423 (35%)], 3-year PFS rates were 13% in the DþT
arm and 4% in the monotherapy arm [HR, 0.61 (95% CI, 0.43–
0.88)] (Figure 1D), and 3-year OS rates were 25% versus 14%
[HR, 0.61 (95% CI, 0.41–0.89)] (Figure 2D). Of 76 DþT-arm
patients with LDH>ULN, 15 (20%) were alive at 3 years and 10
(13%) remained on DþT.
The confirmed response rates per Response Evaluation Criteria
In Solid Tumors (RECIST) were 68% in combination-arm
patients versus 55% in monotherapy patients (Table 1), with a
complete response (CR) rate of 18% versus 15%, respectively.
Median duration of response was 12.0 (95% CI, 9.3–17.1) versus
10.6 (95%CI, 8.3–12.9) months.
With a median time on treatment of 11.8 (range, 0.4–43.7)
versus 8.3 (range, 0.1–45.3) months in DþT-arm and
monotherapy-arm patients, respectively, 49% versus 38%
had>12months of study treatment. Adverse events (AEs) of any
grade, regardless of study drug relationship, were observed in
97% of patients (both arms), with 48% of DþT-arm patients
versus 50% of monotherapy patients experiencing1 grade 3/4
AE (supplementary Table S3, available at Annals of Oncology
online) and 45% versus 38% experiencing serious AEs (supple-
mentary Table S4, available at Annals of Oncology online). The
incidence of several AEs was higher (>10% difference, any
grade) in the DþT versus monotherapy arm: pyrexia (59% ver-
sus 33%), chills (32% versus 17%), diarrhoea (31% versus 17%),
vomiting (26% versus 15%), and peripheral oedema (22% vs
9%) (supplementary Table S4, available at Annals of Oncology
online). Conversely, the incidence of hyperkeratosis (35% versus
7%), alopecia (28% versus 9%), and skin papilloma (22% versus
2%) was higher in monotherapy-arm versus combination-arm
patients (supplementary Table S3, available at Annals of
Oncology online). Palmoplantar hyperkeratosis (18% versus
5%), SCC/KA (7% versus 2%), and basal cell carcinoma (7%
versus 4%) also occurred more frequently in monotherapy-arm
versus DþT-arm patients (supplementary Table S4, available at
Annals of Oncology online). The incidence of other AEs of special
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Figure 1. Continued.
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interest (i.e. cardiotoxicities, ocular events, haemorrhages) was
generally similar across the study arms (supplementary Table S5,
available at Annals of Oncology online).
Notably, the frequency of the most common DþT-associated
AEs, including pyrexia, did not increase by>2% with an addi-
tional 13months of follow-up since the last analysis (supplemen-
tary Table S6, available at Annals of Oncology online). Similarly,
the incidence of key skin-related AEs, including palmoplantar
hyperkeratosis, SCC/KA, and basal cell carcinoma, did not
increase by>1% in the combination arm with extended follow-
up, and no new primary melanomas were observed. Additionally,
occurrence of events leading to dose interruptions (n¼ 122;
58%) or permanent discontinuation (n¼ 29; 14%) in DþT-arm
patients increased by only 2% and 3%, respectively, and no new
grade 5 AEs were observed.
Discussion
This 3-year landmark analysis of COMBI-d represents the longest
follow-up for any phase 3 BRAFi/MEKi combination therapy
trial and provides evidence that long-term clinical benefit and
tolerability are achievable with DþT in a subset of patients with
previously untreated BRAF V600E/K-mutant metastatic mela-
noma. Importantly, these findings do not support the idea that
most patients treated by mitogen-activated protein kinase inhibi-
tors rapidly develop deterioration due to secondary resistance. At
the 3-year landmark, DþT continued to demonstrate superior
benefit versus dabrafenib monotherapy (PFS, 22% versus 12%;
OS, 44% versus 32%), even though 12% of monotherapy patients
crossed over to receive DþT. Furthermore, many patients alive
at 3 years remained on DþT.
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Dabrafenib plus trametinib 133 65% (56–73) 54% (45–62) 0.74
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Figure 2. Overall survival (OS) in the dabrafenib and trametinib (Dþ T) and dabrafenib monotherapy [Dþplacebo (Pbo)] arms in (A) the
intent-to-treat population and patients with (B) normal baseline lactate dehydrogenase (upper limit of normal), (C) normal baseline lactate
dehydrogenase and<3 organ sites with metastasis, and (D) elevated baseline lactate dehydrogenase (>upper limit of normal). CI, confidence
interval; HR, hazard ratio.
aIncludes 25 patients who crossed over from monotherapy to the combination.
bOf patients in the Dþ T arm alive at 3 years, 44 (58%) remained on Dþ T.
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The 3-year OS reported for DþT in this large phase 3 trial
(44%) confirms preliminary results for the smaller corresponding
patient subset in the randomized phase 2 BRF113220 trial (3-year
OS, 38%) [11]. More generally, survival observed in the current
analysis is consistent with previous findings for DþT in BRAF
V600-mutant melanoma, since the 2-year OS reported here
(52%) is similar to that reported in the randomized phase 3
COMBI-v study (51%) and in a pooled analysis across registra-
tion trials (53%) [14]. In this era of multiple drugs with signifi-
cant activity in metastatic melanoma, clinical trial OS results may
be confounded by availability of these therapies. In this analysis,
of patients who received any post-progression systemic therapy,
rates of subsequent anti-PD-1 use were similar between the
DþT and monotherapy arms, and the rate of subsequent ipili-
mumab therapy was numerically higher in the monotherapy arm
compared with the DþT arm. Thus, the 3-year OS observed
with DþT in this study may be mostly attributed to the
combination.
Direct comparisons of survival landmarks across trials of cur-
rently available melanoma treatments should be interpreted with
caution due to differences in baseline characteristics between study
populations, including the requirement for the presence of a BRAF
V600E or V600Kmutation in targeted therapy trials and the period
of time during which studies were conducted (e.g. what treatments
were available for subsequent therapy). However, in the absence of
prospective head-to-head trials evaluating targeted versus
checkpoint-inhibitor immunotherapies, pivotal trials to date can
be considered to provide outcomes trends for each drug class.
Moving forward, it will be important to balance advantages of
immunotherapy with anti-PD-1 (6anti-CTLA-4) and BRAFi/
MEKi combinations.
Follow-up for anti-PD-1 checkpoint-inhibitor immunother-
apy regimens has lagged behind targeted therapy; 3-year land-
mark OS results, as reported here, are currently available only for
early-phase trials. In a phase 1 study evaluating nivolumab
monotherapy in 107 patients with previously treated melanoma,
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Figure 2. Continued.
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unselected for BRAF mutation status and 36% with elevated
LDH, the 2-, 3-, and 5-year OS rates were 48%, 42%, and 34%,
respectively [15]. In a phase 1 study of combined nivolumab plus
ipilimumab, in 53 treatment-naive (60%) or previously treated
(40%) patients with advanced melanoma (38% with elevated
LDH), the 3-year OS was 68%; however, it should be noted that
these results are preliminary [16] and randomized studies of the
combination have shown a consistent 2-year survival of 64% [9,
17], less than this phase 1 landmark. As larger trials evaluating
anti-PD-1 regimens in metastatic melanoma continue follow-up,
preliminary trends in outcomes in a recent meta-analysis demon-
strated no significant difference in OS between first-line BRAFi/
MEKi and anti-PD-1 [18].
Altogether, data across trials of currently available therapies
suggest that long-term survival profiles, at least up to 3 years, do
not seem to confirm the hypothesis that only checkpoint-
inhibitor immunotherapy can provide durable benefit in patients
with metastatic melanoma. Although initial clinical activity (e.g.
response rates) differs between these therapeutic classes [3–9],
the proportion of patients with a 3-year benefit may be similar;
however this will need to be confirmed by additional analyses of
checkpoint-inhibitor immunotherapies specifically in patients
with BRAF-mutant disease. Furthermore, it is important to note
that the plateau survival pattern observed with ipilimumab [2]
has not yet been demonstrated with anti-PD-1 therapies and
remains a potential survival pattern for BRAFi/MEKi.
It is now well established that efficacy of treatment of metastatic
melanoma can differ depending on baseline patient characteristics.
Analyses of BRAFi-naive patients treated with DþT in the phase 2
BRF113220 study and in a pooled analysis across DþT registra-
tion trials identified significant associations between baseline LDH
and number of organ sites containing metastasis and clinical out-
comes [11, 14]. Results from the current analysis support these
findings, with the highest 3-year OS observed among patients with
LDH<ULN and<3 organ sites containing metastasis (DþT,
62%; monotherapy, 45%). Patients with favourable baseline
markers treated with frontline DþT are thus more likely to derive
long-term benefit from this combination. Moreover, although
3-year survival was much lower in patients with LDH>ULN, the
superiority of DþT over dabrafenib monotherapy was main-
tained (3-yearOS, 25% versus 14%).
With an additional 13months of follow-up from the previous
OS analysis of COMBI-d, CR was achieved by an additional 5
DþT-arm patients, resulting in an updated CR rate of 18% and
an overall response rate of 68%with the combination.
The safety profile of DþT with longer follow-up was similar
to that observed in previous analyses, in which the combination
was associated with a reduction in toxicities related to paradoxi-
cal activation of the mitogen-activated protein kinase pathway
compared with BRAFi monotherapy [3, 4, 10–13]. Pyrexia
remained the most common AE with DþT; however, it has been
shown that pyrexia can be managed [19]. The frequency of key
AEs did not greatly change with additional follow-up, including
pyrexia and secondary malignancies, consistent with a recent
report that incidence of DþT-associated AEs is highest during
the first 6months of treatment, declining thereafter [20]. Thus,
although patients who remain on and benefit from treatment can
become an increasingly biased population due to the disappear-
ance of those with very poor tolerance and/or development of
secondary resistance, long-term treatment with DþT appears to
be well tolerated in the subgroup of patients who benefit.
This analysis, representing the longest follow-up for any phase
3 trial evaluating BRAFi/MEKi combination therapy, demon-
strated that long-term survival is achievable with DþT in a rele-
vant proportion of patients with BRAF V600-mutant metastatic
melanoma and that long-term treatment with DþT is tolerable,
with no new safety signals. These results support long-term use of
DþT as a first-line treatment strategy for patients with advanced
BRAFV600-mutant melanoma. However, a more comprehensive
model including clinical factors as described here, along with
molecular and/or immune-markers associated with efficacy, is
needed to further guide treatment decisions (e.g. BRAFi/MEKi
and checkpoint inhibitor immunotherapy sequencing strategies)
in this melanoma population. Continued follow-up planned for
up to 5 years for COMBI-d will provide further understanding of
the extent of benefit achievable with DþT in this setting.
Table 1. Confirmed RECIST response
Dabrafenib plus trametinib Dabrafenib plus placebo
(n 5211) (n 5 212)
RECIST response, n (%)
Complete response (CR) 38 (18) 31 (15)
Partial response (PR) 106 (50) 85 (40)
Stable disease 51 (24) 68 (32)
Progressive disease 12 (6) 18 (8)
Not evaluable 4 (2) 10 (5)
Response rate (CRþ PR), n (%) [95% CI] 144 (68) 116 (55)
[61.5–74.5] [47.8–61.5]
Duration of response n ¼ 144 n ¼ 116
Progressed or died, n (%) 100 (69) 84 (72)
Median (95% CI), months 12.0 (9.3–17.1) 10.6 (8.3–12.9)
CI, confidence interval; RECIST, Response Evaluation Criteria In Solid Tumors.
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